The Lilly COVID-19 antibody trial of the "Pharmaceutical Express" has suspended Theotai's application for listing.

October 14, 2020 / Medical Information List: Lilly COVID-19 antibody trial suspended; Baeotelli's third product filed for market; AstraZeneta/13 weight ADC therapy submitted another clinical trial application in China; Johnson and Johnson 2020Q3 sales of $21.1 billion ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief The State Drug Administration issued a draft of the compulsory insurance management measures for vaccine liability on October 12, the State Drug Administration, together with the National Health And Wellness Commission, the Banking regulatory commission organization drafted the "vaccine liability compulsory insurance management measures (draft for comments)" pointed out that the immunization program vaccine and non-immunization plan vaccine liability compulsory insurance nationwide implementation of a unified minimum liability limit.
compensation for death is not less than 500,000 yuan per person.
(State Drug Administration) CDE issued "Clinical Technical Requirements for Unlisted Drugs In Overseas" on October 12, CDE issued "Clinical Technical Requirements for Unlisted Drugs In Overseas Market", focusing on clinical needs assessment, effectiveness and safety evaluation, racial sensitivity analysis, and benefit/risk assessment of Chinese patients.
(National Drug Administration Drug Audit Center) 662 drugs to reduce prices October 13, Liaoning Province, drugs and medical supplies centralized procurement network issued "on the third batch of state-organized drug centralized procurement of unseeded drug gradient price reduction notice."
Liaoning Province will reduce the prices of other un selected drugs purchased by the Liaoning Provincial Drug and Medical Supplies Centralized Procurement Network, involving a total of 662 drugs, out of the 55 drugs covered in the List of Selected Supply Varieties in the National Drug Central Procurement.
(Liao Pharmaceutical Collection Office) Heilongjiang Province announced the implementation of the third batch of national procurement on October 12, Heilongjiang Provincial Health Insurance Bureau announced "on the implementation of the centralized procurement and use of drugs organized by the state organization notice", will be in November 19, 2020, in the province-wide implementation of the third batch of centralized procurement and use of drugs selected results.
(Heilongjiang Provincial Health Insurance Bureau) four provinces consumables belt procurement came on October 12, Chongqing Municipal Health Insurance Bureau issued the "Chongqing Municipal Health And Health Bureau Chongqing Municipal Drug Administration on the four provinces and cities of medical supplies joint belt procurement and use of the notice", and published the results of the procurement of the volume.
August 13, Chongqing, Guizhou, Yunnan, Henan provinces and cities to carry out centralized procurement of medical supplies.
(Chongqing Municipal Health Insurance Bureau) Part 2 After observing Johnson and Johnson's 2020Q3 sales of $21.1 billion, Johnson and Johnson released its third quarter 2020 results: sales of $21.082 billion, up 1.7% year-on-year;
(Xinhua) -- SQZ Biotech, based in Massachusetts, announced on October 13 that it has filed an IPO application with NASDAQ to raise $75 million for the development of the company's cell therapy-related pipeline.
SQZ Platform, its technology platform, uses physical means to deliver large molecules such as exosumin or genetically modified vectors to cells by extrusion, while ensuring that they do not kill cells.
the proposed IPO of Haihe and Pharmaceuticals, the website of the China Securities Regulatory Commission disclosed a report on Haihe's counseling filings, which are provided by Guotai Junan.
means that Haihe Pharmaceuticals has launched plans for an initial public offering and a listing.
(Pharmaceutical Mission) Part 3 drug information Lilly COVID-19 antibody test was also suspended domestic and foreign "new crown antidote" research and development difficult days ago, following Johnson and Johnson suspended the new crown vaccine clinical trials, Lilly COVID-19 antibody test was also suspended.
trials of COVID-19 therapies and vaccines are still undergoing extensive shoulder reviews, and the path to new crown vaccine development at major drug companies seems to be not going well.
(Sina Pharmaceutical News) AstraZeneca/ First Triple Weight ADC Therapy submitted another clinical trial application in China Today, the CDE website recently announced that the first three in China submitted a new clinical trial application for the antibody consonant drug Enhertu (DS-8201).
HER2-targeted ADC therapy is a key development for AstraZeneta and Phase 3, with a $6.9 billion partnership behind it.
.S. FDA recently announced that it rejected Avenue Therapeutics IV Tramadol's application for a new drug because of safety concerns.
the news, Avenue's share price plunged more than 56 per cent in pre-market trading.
(Sina Pharmaceutical News) Eglin Pharma's second IND was approved by the FDA on October 13, Eglin Pharma announced that the FDA has officially approved its clinical Phase 1 application (IND) for its innovative drug EG-001 for the treatment of idiotic interstitrinal pneumonia.
press release, this is the company's second IND, after its oral capsule EG-009 for the treatment of new coronavirus pneumonia was approved in clinical trials in the United States.
(Pharmaceutical Mission) Howson Pharmaceuticals more than $200 million co-development of CD19 antibody new drug listing application was accepted by CDE today, CDE website recently announced that Viela Bio's anti-CD19 monoclonal antibody in china submitted two new drug listing applications.
first approved in the U.S. in June for the treatment of patients with optic neurospinal cord disease spectrum disorder.
(Pharmaceutical Mission) Haisco Class 1 innovative drug FTP-198 tablets declared clinical acceptance today, Haisco announced that the wholly-owned subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. recently received the State Drug Administration issued a "acceptance notice."
class 1 innovative chemical developed by FTP-198, which is intended to treat idioid pulmonary fibrosis.
(Sina Pharmaceutical News) Yangzijiang attacked 2 billion injection varieties today, CDE official website data show that Yangzijiang Pharmaceutical Group declared the fluorobilofen ester injection class 3 imitation listing application was accepted.
the product is currently only Beijing Ted Pharmaceuticals (China Biopharmaceutical Subsidiary) and Wuhan Da'an Pharmaceuticals received approval, is the first batch of national collection catalog varieties.
(Mininet) Baotai 3 products submitted for listing application today, Baotai research and development of the first class 1 chemical drug Bati non-class injection submitted to the market application, Bati non-ban BAT2094 is a synthetic platelet glycogen II.b/III.a subject antagonist, used for PCI perioperative anti-thrombosis, its clinical dosage form is intravenous injection.
(Drug Newsletter) Lizhu, Qilu the same day into the 5 billion antifellal varieties today, CDE official website data show that Lizhu, Qilu respectively declared the injection of Four types of imitation of Voliconazole market applications, were accepted.
voliconazole for the whole body with antifygal drug TOP1 varieties, leading Pfizer in the domestic generic drug under the constant impact of the market share of only 40%.
(Minenet) Hua-Li Pharmaceuticals obtained Dozagliatin "Drug Production License" Today, Hua-Li Pharmaceuticals announced that after the drug market license holder system audit and on-site verification, the company has been issued by the Shanghai Municipal Drug Administration in the study of the world's first innovative drug Dozagliatin (dorzagliatin) "Drug Production License."
(Agency) Lung cancer 2 targeted drug postoperative aids were given priority approval october 12, Beda Pharmaceuticals acetate, AstraZeneone, AstraZeneta oxytinib tablets two major domestic EGFR targeted drugs have been given priority approval for lung cancer postoperative assistance, for NSCLC adult patients after tumor removal auxiliary treatment.
(CPhI Pharmaceuticals Online) Chinese scientists developed a new therapeutic leukemia vaccine On October 12, researchers from the Institute of Process Engineering of the Chinese Academy of Sciences and Pearl River Hospital of Southern Medical University developed a therapeutic vaccine that encapsulates antigen-based peptides and PD-1 antibodies in self-healing microcapsules to accurately treat leukemia.
in new vaccines, surface peptides and PD-1 antibodies can be efficiently loaded into poly lactic acid microcapsules through the microcapsule's unique self-healing function.
(Biological Exploration)